Clinical and molecular spectrum of RASopathies in a pediatric cohort: A single-center retrospective study
Turkish Journal of Pediatric Disease · 29.04.2026 · 1-8
DOI: 10.12956/tjpd.2026.1301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Pediatric Disease, online erschienen am 29.04.2026. Verfasst von Aslihan Sanri und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Noonan syndrome (NS) and related RASopathies are genetically heterogeneous disorders caused by dysregulation of the RAS/MAPK signaling pathway and are characterized by overlapping clinical features, including distinctive craniofacial appearance, growth impairment, congenital heart defects (CHD), and variable neurodevelopmental involvement. Comprehensive molecular characterization is essential for accurate diagnosis and genotype–phenotype correlation. Evaluation of well-characterized single-center pediatric cohorts may provide clinically relevant real-world insight into genotype–phenotype relationships within routine practice. The aim of this study is to delineate genotype–phenotype correlations in a well-characterized pediatric cohort. Materials and Methods: This retrospective single-center study included pediatric patients between January 2022 and September 2025 with molecularly confirmed diagnosis of NS and related RASopathies. Clinical, laboratory, and imaging findings were reviewed. Targeted next-generation sequencing of RASopathy-associated genes was performed. Detected variants were interpreted according to American College of Medical Genetics and Genomics guidelines, and segregation analysis was conducted when available.
Results
The cohort comprised 20 pediatric patients from 19 unrelated families, with a mean age of 6.1 years. CHD was identified in 80% of patients, most commonly pulmonary valve stenosis (65%), while cardiac involvement was not universal. Short stature was observed in 65% of cases and represented the most frequent reason for referral. Disease-associated variants were identified in nine different genes, with PTPN11 being the most frequently affected (40%), followed by LZTR1 (15%), NF1 (10%), and RAF1(10%). Most variants were classified as pathogenic or likely pathogenic, whereas a limited number were categorized as variants of uncertain significance. Integrated interpretation incorporating phenotype–genotype concordance and segregation data supported the potential clinical relevance of selected uncertain variants.
Conclusion
This pediatric cohort highlights the marked clinical and genetic heterogeneity of NS and related RASopathies. The absence of cardiac involvement in some patients underscores the limitations of phenotype-based assessment alone. Comprehensive molecular testing remains critical for accurate diagnosis, refinement of genotype–phenotype correlations, and appropriate long-term management.
Zitieren
APA
Sanri, A., Cetin, T. K., Usta, E., Mutlu, M. B., Sezer, O., & Sanri, E. (2026). Clinical and molecular spectrum of RASopathies in a pediatric cohort: A single-center retrospective study. Turkish Journal of Pediatric Disease, 1-8. https://doi.org/10.12956/tjpd.2026.1301
Vancouver
Sanri A, Cetin TK, Usta E, Mutlu MB, Sezer O, Sanri E. Clinical and molecular spectrum of RASopathies in a pediatric cohort: A single-center retrospective study. Turkish Journal of Pediatric Disease. 2026:1-8. doi:10.12956/tjpd.2026.1301
BibTeX
@article{Sanri2026,
author = {Sanri, Aslihan and Cetin, Tugba Kontbay and Usta, Emre and Mutlu, Mehmet Burak and Sezer, Ozlem and Sanri, Emre},
title = {Clinical and molecular spectrum of RASopathies in a pediatric cohort: A single-center retrospective study},
journal = {Turkish Journal of Pediatric Disease},
year = {2026},
pages = {1--8},
doi = {10.12956/tjpd.2026.1301}
}
EUVIMED